Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70169 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Ashley L Lennox und 10 weiteren Autor:innen. Beteiligte Einrichtung: Geron Corporation, Foster City, California, USA. Hauptthemen laut MEDLINE: Telomerase, Oligonucleotides, Arrhythmias, Cardiac. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Evaluation of the proarrhythmic potential of imetelstat, a novel oligonucleotide telomerase inhibitor, in nonclinical and clinical studies is presented. In vitro, imetelstat sodium ≤ 750 μg/mL and negative (vehicle) and positive (cisapride) controls were evaluated for hERG channel current inhibition. In vivo, cynomolgus monkeys received a single vehicle control or imetelstat sodium (5 mg/kg [2‐h infusion], 10 mg/kg [6‐h infusion], or 15 mg/kg [6‐ or 24‐h infusion]); cardiovascular parameters were collected before and after drug administration. A ventricular repolarization substudy of the IMerge phase III study evaluated patients with lower‐risk myelodysplastic syndromes administered imetelstat 7.1 mg/kg active dose every 4 weeks; intensive electrocardiograms and pharmacokinetic samples were collected for concentration‐QTc and by‐time point analyses after a single dose. In vitro, imetelstat did not inhibit the hERG channel (IC 50 > 750 μg/mL). In monkeys, imetelstat demonstrated no treatment‐related changes in cardiac parameters, including QTc using Fridericia correction (QTcF). In the IMerge QTc substudy, 45 patients received imetelstat ( n = 29) or placebo ( n = 16). The concentration‐QTc relationship was described by a linear mixed‐effects model; at the geometric mean maximum plasma concentration (C max ) for imetelstat 7.1 mg/kg of 89.5 μg/mL, the predicted effect on placebo‐corrected change from baseline QTcF was 2.36 ms (90% confidence interval, −3.04 to 7.76), supporting no evidence of QTcF prolongation. By‐time point analysis demonstrated no clinically significant effect of imetelstat on QTc. Nonclinical studies demonstrated no proarrhythmic risk at > 140× (in vitro) and > 2.6× (in vivo) imetelstat 7.1 mg/kg C max . Clinical evaluations showed no significant effects on QTcF or other electrocardiogram parameters at 7.1 mg/kg. Collectively, this integrated risk assessment supports the low proarrhythmic potential of imetelstat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geron Corporation, Foster City, California, USA.
- Clario, Philadelphia, Pennsylvania, USA.
- Allucent, Cary, North Carolina, USA.
- Morcos Pharmaceutical Consulting, LLC, Marlboro, New Jersey, USA.
ORCID-Profile: Robert Kleiman
Zitieren
APA
Lennox, A. L., Sun, L., Huang, F., Behrs, M. K., Kleiman, R., Xue, H., Bhise, N., Wan, Y., Berry, T., Feller, F., & Morcos, P. N. (2025). Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.70169
Vancouver
Lennox AL, Sun L, Huang F, Behrs MK, Kleiman R, Xue H, et al. Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis. Clinical and Translational Science. 2025. doi:10.1111/cts.70169
BibTeX
@article{Lennox2025,
author = {Lennox, Ashley L and Sun, Libo and Huang, Fei and Behrs, Melissa Kelly and Kleiman, Robert and Xue, Hongqi and Bhise, Neha and Wan, Ying and Berry, Tymara and Feller, Faye and Morcos, Peter N},
title = {Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70169}
}
EUVIMED